Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Lara Crucitti, Amalia Figuera et al.|Haematologica|2025Cited by 2
Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)Enrico Tiacci, Monia Capponi, Andrea Bernardelli et al.|HemaSphere|2025Cited by 1
Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control StudyAlberto Fresa, Luca Laurenti, Idanna Innocenti et al.|Blood|2024Cited by 0
Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)Enrica Antonia Martino, Federico Vozzella, Raffaella Pasquale et al.|Blood|2024Cited by 0
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control studyAlberto Fresa, Luca Laurenti, Idanna Innocenti et al.|Blood Advances|2025Cited by 0